Survodutide vs Tirzepatide: Dosage, Efficacy & Mechanism
A side-by-side, peer-reviewed comparison of Survodutide and Tirzepatide — mechanism, typical research dose and titration, clinical-trial efficacy, administration, and reconstitution. For research and educational purposes only.
| Attribute | Survodutide | Tirzepatide |
|---|---|---|
| Drug class | Weight Loss | Weight Loss |
| Mechanism of action | Survodutide is a 29-amino-acid lipidated peptide engineered for balanced agonism at the glucagon and GLP-1 receptors (approximately 1:8 GCGR:GLP-1R potency ratio) and has a terminal half-life that supports weekly subcutaneous dosing . The molecule was… | Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP… |
| Typical research dose | 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks). | 2.5–15 mg once weekly (gradual 4‑week titration steps). |
| Headline trial efficacy | Roughly 49% of completers in the 4.8 mg arm achieved at least 15% body-weight loss in the Phase 2 dose-finding trial — comparable to semaglutide at the same time-point . | SUMMIT (Packer et al., NEJM 2024) showed tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38% in patients with obesity-related HFpEF, suggesting cardiovascular benefit beyond glycemia and weight. |
| Administration | Refer to guidelines | Refer to guidelines |
| Vial sizes | 10 mg | 5 mg, 10 mg, 15 mg, 30 mg |
| Storage | Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw. | Lyophilized frozen; reconstituted refrigerated for up to 28 days. |
Frequently Asked Questions
What is the difference between Survodutide and Tirzepatide?expand_more
Survodutide (weight loss) and Tirzepatide (weight loss) differ in receptor target and mechanism. Survodutide is a 29-amino-acid lipidated peptide engineered for balanced agonism at the glucagon and GLP-1 receptors (approximately 1:8 GCGR:GLP-1R potency ratio) and has a terminal half-life that supports weekly subcutaneous dosing . The molecule was… By contrast, tirzepatide: Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP…
How do the typical research doses of Survodutide and Tirzepatide compare?expand_more
Survodutide is typically dosed at 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks)., while Tirzepatide is typically dosed at 2.5–15 mg once weekly (gradual 4‑week titration steps).. See each protocol for the full titration schedule.